Neuroendocrine Tumors - Pipeline Review, H2 2017 Market Report; Launched via MarketResearchReports.com

Neuroendocrine Tumors - Pipeline Review, H2 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.

Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.

Report Highlights

Neuroendocrine Tumors - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 29, 25, 2, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 2 molecules, respectively.

Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).
• The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 467 pages “Neuroendocrine Tumors - Pipeline Review, H2 2017” report covers Introduction, Neuroendocrine Tumors - Overview, Neuroendocrine Tumors - Therapeutics Development, Neuroendocrine Tumors - Therapeutics Assessment, Neuroendocrine Tumors - Companies Involved in Therapeutics Development, Neuroendocrine Tumors - Drug Profiles, Neuroendocrine Tumors - Dormant Projects, Appendix. This report Covered Companies few are - AstraZeneca Plc, AVEO Pharmaceuticals Inc, Boehringer Ingelheim GmbH, Celgene Corp, Cielo Therapeutics Inc, Cleave Biosciences Inc, Crinetics Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Dauntless Pharmaceuticals Inc, DexTech Medical AB, Eli Lilly and Co, Esperance Pharmaceuticals Inc.

Please visit this link for more details: http://mrr.cm/UfD

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017 - Visit at - http://mrr.cm/Ufz

Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2017 - Visit at - http://mrr.cm/UfK